Matching articles for "Trikafta"
Issue 1725 · March 31, 2025 Free
Correction

In our recent article on the combination of vanzacaftor, tezacaftor, and deutivacaftor (Alyftrek) for cystic fibrosis (Med Lett Drugs Ther 2025; 67:41), Table 3 misstated the formulations and dosage of the…

Med Lett Drugs Ther. 2025 Mar 31; 67(1725):56 doi:10.58347/tml.2025.1725d
In our recent article on the combination of vanzacaftor, tezacaftor, and deutivacaftor (Alyftrek) for cystic fibrosis (Med Lett Drugs Ther 2025; 67:41), Table 3 misstated the formulations and dosage of the combination of elexacaftor, tezacaftor, and ivacaftor (Trikafta).
Issue 1724 · March 17, 2025
Vanzacaftor, Tezacaftor, and Deutivacaftor (Alyftrek) for Cystic Fibrosis

The FDA has approved Alyftrek (Vertex) , an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):41-3 doi:10.58347/tml.2025.1724a
The FDA has approved Alyftrek (Vertex) , an oral fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators vanzacaftor, tezacaftor, and deutivacaftor, for once-daily treatment of cystic fibrosis (CF) in patients ≥6 years old who have at least one F508del mutation or another responsive mutation in the CFTR gene. This is the first approval for vanzacaftor and for deutivacaftor, a deuterated form of ivacaftor. Trikafta , a twice-daily oral fixed-dose combination of elexacaftor, tezacaftor, and ivacaftor, is FDA-approved for the same indication in patients ≥2 years old.
Issue 1589 · January 13, 2020
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis

The FDA has approved Trikafta (Vertex), a fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor, and ivacaftor, for oral treatment of…

Med Lett Drugs Ther. 2020 Jan 13; 62(1589):5-7
The FDA has approved Trikafta (Vertex), a fixed-dose combination of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators elexacaftor, tezacaftor, and ivacaftor, for oral treatment of cystic fibrosis (CF) in patients ≥12 years old who have at least one Phe508del mutation in the CFTR gene. About 90% of patients with CF have at least one copy of the Phe508del (also called F508del) mutation. This is the first approval for elexacaftor. Ivacaftor is available alone (Kalydeco) and in 2-drug combinations with tezacaftor (Symdeco) and lumacaftor (Orkambi) .